New & Emerging Technologies 2017-09-22T12:29:15+00:00

We take this opportunity to welcome you to the conference „New and Emerging Technologies“.

The conference „New and Emerging Technologies“ is one of the most visible activities of the glyconet Berlin Brandenburg. As an interdisciplinary networking event, the conference provides a platform for international scientific exchange and showcases the newest developments in glycobiotechnology, biochemistry, molecular biology, biofunctional materials, antibody technologies, synthetic biology and related areas. The scientific program of the conference comprises plenary lectures presented by outstanding scientists as well as poster sessions.

The scientific advisory board from the glyconet Berlin Brandenburg has elaborated a program that will bring together top industry speakers and world-renowned academic scientists to discuss common challenges in a dedicated forum on novel technologies.

The main objective of the event is to share insight on how pioneering technologies and innovative approaches are being applied in order to increase efficiencies and yields, whilst reducing development timelines. Speakers are being invited to share their latest case studies, new/unpublished data and discuss challenges in an open environment that provides practical knowledge and new solutions for teams from across industry, academia and research organizations.

Flyer New_and_Emerging_Technologies_2017

Due to the limited number of participants, an early registration is obligatory.

Conference Flyer

Tell me more about glyconet „New and Emerging Technologies“: please find here our glyconetBB flyer 2017.

Michael Heymann

Time-resolved mix-and-inject serial crystallography combines structural analysis with chemical kinetics to track enzyme catalysis ‘in action’, since the structure of transient states and kinetic mechanisms can be determined simultaneously. These experiments exploit diffusion of a substrate into sample crystals to initiate a reaction and the life-time of a transient reaction intermediate is determined by both the mixing dynamics and the time that the crystals need to travel from the mixing point to the x-ray interaction region. Due to diffusion limited influx of substrate into the crystals, small (nanometer to micrometer sized) crystals are required to achieve millisecond time resolution. We developed a suite of microfluidic methods that utilize high precision 3D printing to overcome long standing challenges in growing and in delivering nano-crystals into the X-ray interaction region of both free-electron lasers and synchrotron sources. Directly imaging catalytic intermediates at the crossover from transition state kinetics to steady state kinetics holds great potential to advance our knowledge of the mechanisms and dynamics of reactions catalyzed by enzymes to inform enzyme design, structure-based drug design, and bio-process engineering.


Dr. Michael Heymann
Department of Cellular and Molecular Biophysics (Schwille lab)
Max Planck Institute of Biochemistry
Am Klopferspitz 18
D-82152 Martinsried, Germany

Nediljko Budisa

The Group of Professor Budisa is well known internationally as a leading team in genetic-code engineering and most recently in chemical synthetic biology (Xenobiology). The research focuses on the development of in vivo methods for introducing genetically-encoded protein modifications in individual proteins, complex protein structures and whole proteomes with the goal to create synthetic cells. The group has also published in the research field of molecular evolution, in particular on the mechanisms and principles of genetics code evolution. They made significant contributions by publishing in the following research areas. (1) Genetic code engineering/expansion for ribosomal translation, synthetic chemistry of unnatural amino acids, fluorine biochemistry, synthetic biology of bio-orthogonal chemistries. (2) Applications of an expanded genetic code to study protein stability/folding, multivalent binding, conformational dynamics, electrostatics, proton and electron transfer & optical properties. (3) Bio-expression of genetically encodable peptide-based drugs and complex biomaterials. (4) Directed evolution of enzymes and bacterial strains & metabolic engineering for artificial biological diversity and technologies derived therefrom. Prof. Budisa also tries to estimate possible societal, ethical and philosophical impacts these scientific and technological achievements.


Prof. Dr. Nediljko Budisa

Technische Universität Berlin
Fakultät II
Institut für Chemie
Sekretariat L 1
Müller-Breslau-Str. 10
10623 Berlin

Telefon: +49 30 314 28960
Telefax: +49 30 314 28279

Anne Zemella

The finite number of twenty amino acids limits their biochemical and biophysical characteristics. Our research is based on a procedure to incorporate chemically modified amino acids with diverse reactive groups into cell-free synthesized proteins at a chosen position. Therefore the amber suppression technology is utilized. We enable the coupling of fluorescence dyes, sugar moieties, PEGylation and biotinylation to the reactive group of the incorporated amino acid by click chemistry. In particular our approach can be further utilized to determine specific conformations of membrane proteins as well as for screening of novel ligands and therapeutics.


Anne Zemella

Cell-free and Cell-based Bioproduction

Fraunhofer Institute for Cell Therapy and Immunology (IZI)

Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam

Science Campus Golm

Am Mühlenberg 13

14476 Potsdam

Marlitt Stech

„ The research group “Cell-free Protein Synthesis” uses cell-free systems based on eukaryotic cell lysates as new strategy for the efficient and reliable synthesis and characterization of antibodies. Compared to conventional methods used for the generation of these proteins, enormous time savings and cost efficiency can be achieved by using cell-free systems as expression and screening platform. Furthermore, these open eukaryotic in-vitro translation systems provide enormous potential for modifications and improvements of the quality and characteristics of cell-free manufactured proteins. One potentially pharmacologically-relevant application, for example, is offered by the cell-free synthesis of antibody-drug conjugates and immunotoxins.”


Dr. Marlitt Stech

Fraunhofer-Institut für Zelltherapie und Immunologie (IZI)

Institutsteil Bioanalytik und Bioprozesse, Potsdam (IZI-BB)

Abteilung Zellfreie und Zellbasierte Bioproduktion

Am Mühlenberg 13, 14476 Potsdam, Germany

Telefon +49 331 58187-305, E-mail: